# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-01-29
**æ›´æ–°æ—¶é—´**: 2026-01-30 04:08
**æ–°é—»æ•°é‡**: 104

---

## ä»Šæ—¥æ¦‚è§ˆ

## ðŸ“Š AI æ™ºèƒ½åˆ†æž

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºŽå¤šé¡¹é‡è¦ç›‘ç®¡å®¡æ‰¹ä¸Žå¤§åž‹æˆ˜ç•¥æŠ•èµ„ã€‚FDAæ‰¹å‡†äº†å¤šæ¬¾åˆ›æ–°ç–—æ³•ï¼ŒåŒ…æ‹¬Tenpointçš„è€èŠ±çœ¼æ»´çœ¼æ¶²å’Œå¼ºç”ŸDarzalex Fasproåœ¨å¤šå‘æ€§éª¨é«“ç˜¤ä¸­çš„æ–°é€‚åº”ç—‡ï¼›åŒæ—¶ï¼Œé˜¿æ–¯åˆ©åº·å®£å¸ƒå°†åœ¨ä¸­å›½æŠ•èµ„150äº¿ç¾Žå…ƒä»¥å¢žå¼ºç»†èƒžç–—æ³•å’Œæ”¾å°„æ€§å¶è”è¯ç‰©èƒ½åŠ›ï¼Œæ˜¾ç¤ºå‡ºè·¨å›½è¯ä¼å¯¹ä¸­å›½å¸‚åœºçš„é•¿æœŸæ‰¿è¯ºã€‚æ­¤å¤–ï¼ŒåŸºå› ç–—æ³•é¢†åŸŸå‡ºçŽ°å®‰å…¨æ‹…å¿§ï¼ŒRegenxbioçš„ä¸¤é¡¹è¯•éªŒå› æ‚£è€…å‡ºçŽ°è„‘è‚¿ç˜¤è¢«FDAæš‚åœã€‚

### ðŸ”¥ é‡ç‚¹æ–°é—»

**11. AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities** â­â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - 150äº¿ç¾Žå…ƒå·¨é¢æŠ•èµ„å½°æ˜¾å¯¹ä¸­å›½å¸‚åœºçš„æˆ˜ç•¥æŠ¼æ³¨ï¼Œå°†æ˜¾è‘—å¢žå¼ºå…¶åœ¨ç»†èƒžç–—æ³•å’Œæ”¾å°„æ€§å¶è”è¯ç‰©ç­‰å‰æ²¿é¢†åŸŸçš„èƒ½åŠ›ã€‚

**1. Tenpoint wins FDA nod for combination presbyopia eye drop** â­â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - FDAæ‰¹å‡†æ–°åž‹è€èŠ±çœ¼æ»´çœ¼æ¶²ï¼Œå¹¶ä¼´éš2.35äº¿ç¾Žå…ƒèžèµ„æ”¯æŒä¸Šå¸‚ï¼Œæœ‰æœ›æŒ‘æˆ˜è‰¾ä¼¯ç»´ç­‰çŽ°æœ‰ç–—æ³•ã€‚

**13. J&J sharpens Darzalex's edge with quadruplet FDA nod in newly diagnosed multiple myeloma** â­â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - Darzalex FasproèŽ·å¾—FDAæ–°æ‰¹å‡†ç”¨äºŽä¸é€‚åˆå¹²ç»†èƒžç§»æ¤çš„æ–°è¯Šæ–­å¤šå‘æ€§éª¨é«“ç˜¤æ‚£è€…ï¼Œå·©å›ºå…¶å¸‚åœºé¢†å…ˆåœ°ä½ã€‚

**16. Regenxbio gene therapy trials suspended by FDA over safety worries** â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - å› ä¸€åå‚ä¸Žè€…å‡ºçŽ°è„‘è‚¿ç˜¤ï¼ŒFDAæš‚åœä¸¤é¡¹åŸºå› ç–—æ³•è¯•éªŒï¼Œå¼•å‘å¯¹åŸºå› ç–—æ³•å®‰å…¨æ€§çš„æ–°å…³æ³¨ã€‚

**2. FDA lifts hold on an Intellia CRISPR drug trial** â­â­â­â­
   - ç±»åˆ«: ç›‘ç®¡å®¡æ‰¹
   - FDAè§£é™¤å¯¹Intellia CRISPRè¯ç‰©è¯•éªŒçš„éƒ¨åˆ†æš‚åœï¼Œä½†ä¸€é¡¹è¯•éªŒä»æš‚åœï¼Œæ˜¾ç¤ºåŸºå› ç¼–è¾‘ç–—æ³•ç›‘ç®¡çš„å®¡æ…Žå¹³è¡¡ã€‚

### ðŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): ä»Šæ—¥æ–°è¯ç ”å‘æ´»åŠ¨æ´»è·ƒï¼Œæ¶‰åŠå¤šä¸ªå‰æ²¿é¢†åŸŸã€‚Lillyä¸ŽSeamlessè¾¾æˆæ½œåœ¨ä»·å€¼10äº¿ç¾Žå…ƒçš„åŸºå› ç¼–è¾‘åˆä½œï¼Œå¼€å‘å¬åŠ›æŸå¤±ç–—æ³•ï¼›Argo Biopharmaçš„siRNAç–—æ³•BWâ€‘20829è¿›å…¥IIbæœŸè¯•éªŒï¼›Agomabè®¡åˆ’é€šè¿‡IPOèžèµ„æŽ¨è¿›çº¤ç»´åŒ–ç®¡çº¿ï¼›èµ›è¯ºè²åˆ™å‰Šå‡äº†åŒ…æ‹¬amlitelimabåœ¨å†…çš„å¤šä¸ªç ”å‘é¡¹ç›®ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): ä¸´åºŠè¯•éªŒæ–¹é¢å‡ºçŽ°æ˜¾è‘—çš„å®‰å…¨æ€§ä¸Žè¿›å±•ä¿¡å·ã€‚Regenxbioçš„ä¸¤é¡¹åŸºå› ç–—æ³•è¯•éªŒå› æ‚£è€…å‡ºçŽ°è„‘è‚¿ç˜¤è¢«FDAæš‚åœï¼Œå¼•å‘å®‰å…¨æ‹…å¿§ã€‚Intelliaçš„CRISPRè¯•éªŒåœ¨å®žæ–½æ–°ä¿éšœæŽªæ–½åŽéƒ¨åˆ†æ¢å¤ã€‚ç½—æ°å±•ç¤ºäº†å…¶GLP-1æ³¨å°„å‰‚çš„æ–°æ•°æ®ï¼Œè¯•å›¾åœ¨è‚¥èƒ–ç—‡é¢†åŸŸè¿½èµ¶ã€‚Summit Therapeuticsçš„PD-1xVEGFåŒç‰¹å¼‚æ€§æŠ—ä½“èŽ·å¾—FDAçš„PDUFAæ—¥æœŸã€‚

### ðŸ”® æ˜Žæ—¥å…³æ³¨

æ˜Žæ—¥å€¼å¾—å…³æ³¨çš„äº‹é¡¹åŒ…æ‹¬ï¼š1) åŸºå› ç–—æ³•å®‰å…¨äº‹ä»¶ï¼ˆå¦‚Regenxbioå’ŒIntelliaæ¡ˆä¾‹ï¼‰å¯èƒ½å¼•å‘çš„æ›´å¹¿æ³›è¡Œä¸šè®¨è®ºä¸Žç›‘ç®¡ååº”ï¼›2) é˜¿æ–¯åˆ©åº·å¯¹ä¸­å›½çš„å¤§è§„æ¨¡æŠ•èµ„ç»†èŠ‚åŠå…¶å¯¹å…¨çƒç»†èƒžç–—æ³•ç«žäº‰æ ¼å±€çš„æ½œåœ¨å½±å“ï¼›3) æ¬§ç›Ÿä¸Žå°åº¦è‡ªç”±è´¸æ˜“åå®šä¸­å–æ¶ˆè¯å“å‡ºå£å…³ç¨Žçš„è¿›å±•ï¼ŒåŠå…¶å¯¹å…¨çƒä¾›åº”é“¾å’Œå®šä»·çš„å½±å“ï¼›4) èµ›è¯ºè²ä¸ºåº”å¯¹Dupixentä¸“åˆ©æ‚¬å´–è€Œè®¡åˆ’çš„140-150äº¿æ¬§å…ƒå¹¶è´­é¢„ç®—çš„å…·ä½“åŠ¨å‘ã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |
| ç»¼åˆ (ç»¼åˆ) | 42 |

---

## æ–°è¯ç ”å‘ | Drug R&D

### ðŸ‡ºðŸ‡¸ Tenpoint wins FDA nod for combination presbyopia eye drop

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 12:26
- **é‡è¦æ€§**: â­â­â­â­

> The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an advance over existing treatments from AbbVie and others.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/tenpoint-yuvezzi-fda-approve-presbyopia-eye-drop/810743/)

---

### ðŸ‡ºðŸ‡¸ FDA lifts hold on an Intellia CRISPR drug trial

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-27 16:59
- **é‡è¦æ€§**: â­â­â­â­

> Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/intellia-fda-lifts-hold-nex-z-crispr-ttr-amyloidosis/810584/)

---

### ðŸ‡ºðŸ‡¸ Lilly bets on Seamless, delving further into genetic medicine for hearing loss

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-28 19:09
- **é‡è¦æ€§**: â­â­

> The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/eli-lilly-seamless-deal-gene-editing-hearing-loss/810694/)

---

### ðŸ‡ºðŸ‡¸ Regenxbio gene therapy trials suspended by FDA over safety worries

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-28 16:06
- **é‡è¦æ€§**: â­â­

> The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing and a treatment for Hunter syndrome nearing an FDA decision.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/regenxbio-fda-hold-hunter-hurler-syndrome-gene-therapy/810691/)

---

### ðŸ‡ºðŸ‡¸ Roche, trailing in obesity, showcases new data for GLP-1 shot

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-27 16:31
- **é‡è¦æ€§**: â­â­

> A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/roche-obesity-drug-phase-2-data-carmot-glp-gip/810578/)

---

### ðŸ‡ºðŸ‡¸ Pipeline cuts for Sanofi; Breakthru Medicine raises $60M

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 15:42
- **é‡è¦æ€§**: â­â­

> âœ‚ï¸ Sanofi culls several programs: The move comes as part of its â€œregular portfolio reviews,â€ a spokesperson said in an email. One candidate affected was amlitelimab, which is no longer in mid-stage trials for alopecia ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/sanofis-pipeline-cuts-breakthru-medicine-raises-60m/)

---

### ðŸ‡ºðŸ‡¸ Summit gets November PDUFA date for its PD-1xVEGF bispecific

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 15:07
- **é‡è¦æ€§**: â­â­

> The leader in the next frontier of immuno-oncology officially has a date with the FDA. Summit Therapeutics announced Thursday morning that US regulators have accepted its submission package for the experimental drug ivonescimab, a bispecific ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/summit-gets-november-pdufa-date-for-its-pd-1xvegf-bispecific/)

---

### ðŸ‡ºðŸ‡¸ Agomab anticipates $182M IPO as it builds fibrosis pipeline

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 14:13
- **é‡è¦æ€§**: â­â­

> Belgian fibrosis biotech Agomab Therapeutics plans to collect about $182 million in net proceeds from its proposed Nasdaq IPO. The company anticipates selling 12.5 million shares at $15 to $17 each under the ticker symbol ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/agomab-anticipates-182m-ipo-as-it-builds-fibrosis-pipeline/)

---

### ðŸ‡ºðŸ‡¸ Sanofi says its â‚¬15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 11:46
- **é‡è¦æ€§**: â­â­

> Sanofi says it will be able to spend between â‚¬14 billion and â‚¬15 billion on M&amp;A deals this year while still being able to meet its financial commitments. â€œIt doesnâ€™t mean that we will make ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/sanofi-says-its-e15b-dealmaking-budget-rd-spend-should-help-ease-looming-dupixent-patent-cliff/)

---

### ðŸ‡ºðŸ‡¸ Tenpoint gets FDA nod for presbyopia eye drop and $235M

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 06:08
- **é‡è¦æ€§**: â­â­

> Tenpoint Therapeutics landed an FDA approval for its presbyopia eye drop on Wednesday, entering a tricky commercial landscape for therapeutic alternatives to reading glasses and contacts. In conjunction with the approval ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/tenpoint-gets-fda-nod-for-presbyopia-eye-drop-and-235m/)

---

### ðŸ‡ºðŸ‡¸ Oral Rogaine maker Veradermics looks to raise $181M from IPO

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 19:18
- **é‡è¦æ€§**: â­â­

> Veradermics, a biotech in late-stage testing with an oral version of Rogaine, is looking to raise $181.8 million in net proceeds from its proposed IPO. The Connecticut biotech will garner that amount if it sells ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/oral-rogaine-maker-veradermics-looks-to-raise-181m-from-ipo/)

---

### ðŸ‡ºðŸ‡¸ FDA asks court to pause Louisiana's abortion pill fight

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 19:18
- **é‡è¦æ€§**: â­â­

> The Trump administration is asking a federal court to halt a case over the abortion pill mifepristone while the FDA undertakes a review of the drugâ€™s safety protocols. An ongoing mifepristone review could result in ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/fda-asks-court-to-pause-louisianas-abortion-pill-fight/)

---

### ðŸ‡ºðŸ‡¸ FDA suspends two Regenxbio gene therapy trials after patient developed brain tumor

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 15:56
- **é‡è¦æ€§**: â­â­

> The FDA has placed studies of two gene therapies from Regenxbio on hold after a five-year-old patient in one of the trials was found to have a brain tumor. The drug regulator's decision is a ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/fda-suspends-regenxbio-gene-therapy-trials-after-patient-developed-brain-tumor/)

---

### ðŸ‡ºðŸ‡¸ Updated: Roche predicts its breast cancer pill could become its biggest-selling drug

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 12:11
- **é‡è¦æ€§**: â­

> With two positive clinical readouts in the bag, a US approval filing, and another important trial due to report in a couple months, Rocheâ€™s breast cancer drug giredestrant is sitting pretty. Management is hugely confident ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/roche-predicts-its-breast-cancer-pill-could-become-its-biggest-selling-drug/)

---

### ðŸ‡ºðŸ‡¸ The biopharma industry outlook on 2026: Optimism and tension

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 19:31

> A spike in M&amp;A activity and stock prices have pulled biotech out of a yearslong downturn. But regulatory tumult and fierce competition from China could short-circuit the sector's resurgence.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/biotech-pharma-trends-outlook-2026/810833/)

---

### ðŸ‡ºðŸ‡¸ Sanofi expects vaccine sales growth to dip amid â€˜challenging environmentâ€™

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 16:56

> On a conference call, executives cited &ldquo;confusion&rdquo; and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated slower growth in 2026. &nbsp;

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/sanofi-vaccine-sales-fourth-quarter-2025-earnings/810829/)

---

### ðŸ‡ºðŸ‡¸ AstraZeneca strengthens China ties with planned $15B investment

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-29 15:46

> AstraZeneca&rsquo;s&nbsp;investment will &ldquo;span the value chain&rdquo; of drug research and development and comes amid a prolonged surge in dealmaking activity involving large pharmaceutical companies and their counterparts in China.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/astrazeneca-china-biotech-invest-drug-manufacturing/810847/)

---

### ðŸ‡ºðŸ‡¸ Drugs for cancer, arthritis and HIV on Medicareâ€™s list for 2028 price cuts

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-28 16:51

> Still, the medications in the latest round of negotiations &mdash; which now includes &ldquo;Part B&rdquo; drugs given in doctors offices &mdash; draw very limited revenue from Medicare, an analyst pointed out.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/medicare-drug-price-2028-trulicity-biktarvy-verzenio-kisqali/810688/)

---

### ðŸ‡ºðŸ‡¸ Halozyme buys a biotech startup; Cytokinetics launches heart drug

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-28 16:20

> Halozyme is paying as much as $400 million for a drug delivery specialist that could boost its growth prospects, one analyst wrote. Elsewhere, Boehringer dipped into China for a bispecific drug and a trans-Atlantic VC firm restocked.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.biopharmadive.com/news/halozyme-surf-myqorzo-boehringer-china-gsk-rsv-epidarex/810539/)

---

### ðŸ‡ºðŸ‡¸ Takeda 'anticipated' Medicare negotiations for top seller Entyvio

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 19:06

> Incoming Takeda CEO Julie Kim says the drugmaker "anticipated" this week's selection of Entyvio for Medicare negotiations. But for now, the company isn't ready to comment on how the process could affect peak revenue forecasts ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/takeda-anticipated-medicare-negotiations-for-top-seller-entyvio/)

---

### ðŸ‡ºðŸ‡¸ Takeda is â€˜not in favorâ€™ of Trumpâ€™s MFN deals, CEO-designate says

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 18:01

> Takedaâ€™s incoming CEO took a firm stance against President Donald Trumpâ€™s â€œmost favored nationâ€ deals with drugmakers on Thursday, while Sanofi and Roche shared new details about their negotiations with the White House. â€œIn general ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/takeda-is-not-in-favor-of-trumps-mfn-deals-ceo-designate-says/)

---

### ðŸ‡ºðŸ‡¸ White House postpones planned TrumpRx launch event

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 17:57

> The White House is punting the launch of TrumpRx, the administrationâ€™s hub for direct-to-consumer websites run by large drugmakers. The event was expected to take place Friday, but itâ€™s been postponed, two sources familiar with ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/white-house-postpones-planned-trumprx-launch-event/)

---

### ðŸ‡ºðŸ‡¸ Sanofi vows to stay committed to vaccines as portfolio takes a hit

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 16:18

> Sanofi CEO Paul Hudson emphasized the companyâ€™s commitment to vaccine development in the face of an increasingly challenging sales environment and its decision to abandon an mRNA-based flu vaccine program. â€œWe have to continue to ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/sanofi-vows-to-stay-committed-to-vaccines-as-portfolio-takes-a-hit/)

---

### ðŸ‡ºðŸ‡¸ The disrupted fate of pharmacy startups

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 16:14

> Last week, the House Judiciary Committee came out with a report about CVS Healthâ€™s alleged antitrust behavior toward disruptive pharmacy models that provide digital services to other pharmacies. It details ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/the-disrupted-fate-of-pharmacy-startups/)

---

### ðŸ‡ºðŸ‡¸ Trump looks to raise South Korea levies; Siegfried expands

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 14:42

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/trump-looks-to-raise-south-korea-levies-siegfried-expands/)

---

### ðŸ‡ºðŸ‡¸ AstraZeneca makes $15B bet on China to expand manufacturing and R&D

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 13:39

> AstraZeneca, already one of the leading pharmaceutical companies in China, is extending its reach in the country that's become a go-to place for drug R&amp;D and industry dealmaking in the past year. The UK pharma ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/astrazeneca-makes-15b-bet-on-china-to-expand-manufacturing-and-rd/)

---

### ðŸ‡ºðŸ‡¸ Premise Health to merge with Crossover Health to expand employer clinics

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 13:00

> Two companies that run on-site health clinics for employers like Google and Amazon are merging as healthcare costs continue to climb. Advanced primary care company Premise Health is acquiring competitor Crossover Health. Both run clinics ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/premise-health-to-merge-with-crossover-health-to-expand-employer-clinics/)

---

### ðŸ‡ºðŸ‡¸ Following Abivax, Formation Bio licenses miR-124 drug from China

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 12:00

> The French biotech Abivax was a biotech market standout for 2025. Formation Bio now wants a piece of that success. The privately-held New York pharma startup has licensed a small molecule aimed ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/exclusive-following-abivax-formation-bio-licenses-mir-124-drug-from-china/)

---

### ðŸ‡ºðŸ‡¸ Flagship's Repertoire gets another autoimmune partner in Lilly

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-29 11:30

> Repertoire Immune Medicines has added a fourth pharmaceutical partner by teaming up with Eli Lilly. The Indianapolis pharma joins Bristol Myers Squibb and Genentech in allying with Repertoire on so-called tolerizing vaccines for autoimmune diseases ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/flagships-repertoire-gets-another-autoimmune-partner-in-lilly/)

---

### ðŸ‡ºðŸ‡¸ ChenMed CEO warns against GLP-1s for seniors

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 23:12

> ChenMed CEO Chris Chen said the primary care chain isnâ€™t encouraging the use of GLP-1 drugs for weight loss after finding the medications led to worse health outcomes among its older patients. Speaking on a ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/chenmed-ceo-warns-against-glp-1s-for-seniors/)

---

### ðŸ‡ºðŸ‡¸ Round three of IRA negotiations is expected to be â€˜manageableâ€™ for pharma

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 21:19

> Drugmakers will likely be able to handle the impacts of the third round of Medicare negotiations, analysts say, even as the biopharma industry continues to criticize the Biden-era program. On Tuesday, CMS

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/round-three-of-ira-negotiations-is-expected-to-be-manageable-for-pharma/)

---

### ðŸ‡ºðŸ‡¸ Lonza still intends to sell its capsules and health ingredients business

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 18:51

> More than a year after Lonza announced it will sell its capsules and health business, the Swiss CDMO said it has yet to finalize the deal with a buyer. A spokesperson said it has multiple ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/lonza-still-intends-to-sell-its-capsules-and-health-ingredients-business/)

---

### ðŸ‡ºðŸ‡¸ Teva CEO says it has successfully transitioned into a biopharma company

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 17:18

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/teva-ceo-says-it-has-successfully-transitioned-into-a-biopharma-company/)

---

### ðŸ‡ºðŸ‡¸ HHS seeks to protect drugmakers from violating anti-kickback laws ahead of TrumpRx launch

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-28 15:26

> With launch time potentially approaching for TrumpRx, HHS unveiled part of its plan to shield drugmakers from anti-kickback laws to allow them to sell their products on the new direct-to-consumer platform. The guidance â€” released via ...

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://endpoints.news/hhs-seeks-to-protect-drugmakers-from-anti-kickback-laws-ahead-of-trumprx-launch/)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ðŸ‡ºðŸ‡¸ FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 19:37
- **é‡è¦æ€§**: â­â­â­â­

> On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cel

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly)

---

### ðŸ‡ºðŸ‡¸ Oncology (Cancer)/Hematologic Malignancies Approval Notifications

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 17:55
- **é‡è¦æ€§**: â­â­â­â­

> FDA does not&nbsp;issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to&nbsp;Drugs@FDA&nbsp;for the latest approvals and prescribing information for specific products.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications)

---

### ðŸ‡ºðŸ‡¸ Clinical Decision Support Software

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 16:11
- **é‡è¦æ€§**: â­â­â­

> This guidance clarifies the scope of FDAâ€™s oversight of clinical decision support software intended for health care professionals (HCPs) as devices.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-decision-support-software)

---

### ðŸ‡ºðŸ‡¸ GDUFA IV: Fiscal Years 2028 â€“ 2032

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 22:36
- **é‡è¦æ€§**: â­â­

> Information related to FDAâ€™s preparation for the fourth reauthorization of GDUFA will be hosted on this page as it becomes available.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/gdufa-iv-fiscal-years-2028-2032)

---

### ðŸ‡ºðŸ‡¸ Untitled Letters

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 18:35
- **é‡è¦æ€§**: â­â­

> These letters are supplied by the CDER Freedom of Information Office and only cover Office of Prescription Drug Promotion's untitled letters. FDA may have redacted or edited some of the letters to remove confidential information.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/warning-letters-and-notice-violation-letters-pharmaceutical-companies/untitled-letters)

---

### ðŸ‡ºðŸ‡¸ Prescription Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 15:41
- **é‡è¦æ€§**: â­â­

> The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products. Since the passage of PDUFA, user fees have played an important role in expediting the drug approval process.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments)

---

### ðŸ‡ºðŸ‡¸ Over-The-Counter Monograph Drug User Fee Program (OMUFA)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 15:29
- **é‡è¦æ€§**: â­â­

> A user fee program for nonprescription (over-the-counter or OTC) monograph drugs would be a potential funding mechanism to supplement congressional non user-fee appropriations.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/over-counter-monograph-drug-user-fee-program-omufa)

---

### ðŸ‡ºðŸ‡¸ Medication Health Fraud for Specific Diseases and Conditions

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-28 19:11
- **é‡è¦æ€§**: â­â­

> FDA has identified condition-specific medication health fraud scams that can pose significant risks to consumers.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/medication-health-fraud/medication-health-fraud-specific-diseases-and-conditions)

---

### ðŸ‡ºðŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-28 16:31
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ðŸ‡ºðŸ‡¸ A Special Year, New Seal, and Renewed Commitment to the American People

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-28 14:55
- **é‡è¦æ€§**: â­â­

> The FDA has unveiled an official agency seal which signifies the many public health strides made over 120 years.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/news-events/fda-voices/special-year-new-seal-and-renewed-commitment-american-people)

---

### ðŸ‡ºðŸ‡¸ Project Orbis

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 20:13
- **é‡è¦æ€§**: â­â­

> Information Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE) that provides a framework for concurrent submission and review of oncology products among international partners.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/about-fda/oncology-center-excellence/project-orbis)

---

### ðŸ‡ºðŸ‡¸ What Does FDA Approve? Part 2

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 19:23
- **é‡è¦æ€§**: â­â­

> The growing spread of rumors, misinformation and disinformation about science, medicine, and the FDA, is putting patients and consumers at risk. FDA is here to provide the facts.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/consumers/consumer-updates/what-does-fda-approve-part-2)

---

### ðŸ‡ºðŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 17:56
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ðŸ‡ºðŸ‡¸ Reviews of Pediatric Studies Conducted under BPCA and Pediatric assessments conducted under PREA from 2012 â€“ present

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 15:26
- **é‡è¦æ€§**: â­

> The following are the medical, statistical, and clinical pharmacology reviews of pediatric studies conducted in response to a Written Request issued under the BPCA and pediatric assessments conducted under PREA.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/development-resources/reviews-pediatric-studies-conducted-under-bpca-and-pediatric-assessments-conducted-under-prea-2012)

---

### ðŸ‡ºðŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 22:40

> Generic Drug Facilities, Sites and Organization Lists

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ðŸ‡ºðŸ‡¸ OMUFA Reauthorization: Fiscal Years 2026 - 2030

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 17:20

> This page is the main website for information pertaining to OMUFA reauthorization activities, including high level meeting minutes with industry while negotiations are ongoing.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/omufa-reauthorization-fiscal-years-2026-2030)

---

### ðŸ‡ºðŸ‡¸ Human Drug Compounding Outsourcing Facility Fees

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-29 15:14

> Human Drug Compounding Outsourcing Facility Fees

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/human-drug-compounding-outsourcing-facility-fees)

---

### ðŸ‡ºðŸ‡¸ Patent Certifications and Suitability Petitions

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 19:00

> Information on patents and suitability petitions that impact the availability of generic drugs.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions)

---

### ðŸ‡ºðŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 17:22

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ðŸ‡ºðŸ‡¸ Center For Immunology Science, LLC - 719933 - 01/13/2026

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-27 14:20

> Sponsor/Investigator

ðŸ”— [é˜…è¯»åŽŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/center-immunology-science-llc-719933-01132026)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ðŸ‡ºðŸ‡¸ Argo Biopharma doses first patient in phase 2b trial of BWâ€‘20829

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-28 14:20
- **é‡è¦æ€§**: â­â­â­

> siRNA therapeutic progresses in global study for patients with elevated Lp(a)

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/argo-biopharma-doses-first-patient-in-phase-2b-trial-of-bw-20829/)

---

### ðŸ‡ºðŸ‡¸ Otsuka Pharmaceuticalâ€™s Dawnzera receives EC approval for hereditary angioedema prevention

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-26 12:05
- **é‡è¦æ€§**: â­â­

> Dawnzera showed an 81% reduction in the four-weekly rate of HAE attacks compared to placebo

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/otsuka-pharmaceuticals-dawnzera-receives-ec-approval-for-hereditary-angioedema-prevention/)

---

### ðŸ‡ºðŸ‡¸ CERo reports encouraging early data from phase 1 trial of CERâ€‘1236

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-29 10:59
- **é‡è¦æ€§**: â­

> CERâ€‘T therapy shows initial safety signals and prompts protocol expansion

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/cero-reports-encouraging-early-data-from-phase-1-trial-of-cer-1236/)

---

### ðŸ‡ºðŸ‡¸ ENA Respiratory begins dosing in phase 2 study of INNAâ€‘051 nasal spray

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-29 10:44
- **é‡è¦æ€§**: â­

> Trial to assess whether onceâ€‘weekly treatment can reduce symptomatic viral respiratory infections

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/ena-respiratory-begins-dosing-in-phase-2-study-of-inna-051-nasal-spray/)

---

### ðŸ‡ºðŸ‡¸ BioMed X launches kidney disease project in partnership with the government of Barbados

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-27 13:54
- **é‡è¦æ€§**: â­

> Initiative focuses on population-specific molecular profiling

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/biomed-x-launches-kidney-disease-project-in-partnership-with-the-government-of-barbados/)

---

### ðŸ‡ºðŸ‡¸ Akari files new patent and advances second ADC targeting CEACAM5

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-28 14:15

> Company strengthens pipeline with AKTX-102 as it broadens its intellectual property estate

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/akari-files-new-patent-and-advances-second-adc-targeting-ceacam5/)

---

### ðŸ‡ºðŸ‡¸ Gedeon Richter UK takes over UK rights to cariprazine

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-27 13:47

> Company strengthens its neuropsychiatry portfolio after marketing transfer from Recordati

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/gedeon-richter-uk-takes-over-uk-rights-to-cariprazine/)

---

### ðŸ‡ºðŸ‡¸ Corcept Therapeuticsâ€™ relacorilant plus nab-paclitaxel shows positive results in ovarian cancer

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-26 11:57

> Ovarian cancer is the fifth leading cause of deaths from cancer in women

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://pharmatimes.com/news/corcept-therapeutics-relacorilant-plus-nab-paclitaxel-shows-positive-results-in-ovarian-cancer/)

---

## ç»¼åˆ | ç»¼åˆ

### ðŸ‡ºðŸ‡¸ ARS Pharma TV ad for epinephrine nasal spray Neffy needled by FDA in untitled letter

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 11:46
- **é‡è¦æ€§**: â­â­

> A few months after sending an untitled letter to ARS Pharmaceuticals, taking issue with certain aspects of a TV commercial about its epinephrine nasal spray, the FDA is reiterating its concerns about Neffyâ€™s advertising language.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/ars-pharma-tv-ad-epinephrine-nasal-spray-neffy-needled-fda-untitled-letter)

---

### ðŸ‡ºðŸ‡¸ Sanofiâ€™s vaccine ambitions unfazed by â€˜politics or sentiment in the now,â€™ CEO Hudson says

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 11:22
- **é‡è¦æ€§**: â­â­

> Amid mounting concerns about the state of vaccine policy in the United States, Sanofi is keeping a cool head while acknowledging that sales of its immunizations are slated to dip slightly this year. The comments come as Sanofi reported Thursday that its total vaccine sales fell 2.5% in the fourth quarter and 1.2% for the entire year, reaching 7.9 billion euros (roughly $9.5 billion) for all of 2025.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/sanofi-stands-firm-against-us-policy-tumult-it-predicts-vaccine-sales-dip-26)

---

### ðŸ‡ºðŸ‡¸ 'Relax your tight end': Novartis Super Bowl ad drafts NFL stars for cheeky prostate cancer testing push

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 16:56
- **é‡è¦æ€§**: â­â­

> A year after debuting its first Super Bowl ad, Novartis is returning to advertisingâ€™s biggest stage on another awareness-raising mission, this time focusing on boosting prostate cancer screening.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/novartis-super-bowl-ad-drafts-nfl-stars-cheeky-prostate-cancer-testing-push)

---

### ðŸ‡ºðŸ‡¸ Tenpoint scores FDA nod for vision-correction eye drop Yuvezzi, plans Q2 launch with $235M in tow

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 23:53
- **é‡è¦æ€§**: â­â­

> Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA approval for Yuvezzi, a treatment for presbyopia, a common, age-related condition that makes it difficult to focus on nearby objects. The company also said that it has raised $235 million to fund the launch of the product.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/tenpoint-scores-fda-nod-vision-correction-eye-drop-yuvezzi)

---

### ðŸ‡ºðŸ‡¸ AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 05:51
- **é‡è¦æ€§**: â­â­

> AstraZeneca has outlined plans to invest $15 billion in China through 2030, making a broad commitment to the country to enhance its capabilities in areas including cell therapies and radioconjugates.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/biotech/astrazeneca-vows-15b-china-investment-boost-cell-therapy-and-radioconjugate-capabilities)

---

### ðŸ‡ºðŸ‡¸ Antheia seals 2nd series C funding close, hitting more than $175M in a year

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 08:26
- **é‡è¦æ€§**: â­â­

> Biosynthesis specialist Antheia has topped off its series C funding with a second close, adding $24 million more to its haul. The financing lift brings Antheia's total funding over the past year to more than $175 million when combined with other capital and new contracts with the U.S. government, according to the company.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/antheia-seals-second-close-series-c-funding-hit-175m-year)

---

### ðŸ‡ºðŸ‡¸ J&amp;J sharpens Darzalex's edge with quadruplet FDA nod in newly diagnosed multiple myeloma

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 18:23
- **é‡è¦æ€§**: â­â­

> A new FDA nod for autologous stem cell transplant-ineligible patients fortifies Darzalex Faspro's position for patients with newly diagnosed multiple myeloma.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/jjs-darzalex-faspro-expands-its-first-line-offerings-fda-nod-quadruplet-multiple-myeloma)

---

### ðŸ‡ºðŸ‡¸ EU looks to knock out pharmaceutical export tariffs in sweeping free trade pact with India

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 11:13
- **é‡è¦æ€§**: â­â­

> Nearly two decades after the parties first floated the idea of a free trade agreement, the turbulence of the global market has prompted the EU and India to carry their deal across the finish line.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/eu-looks-knock-out-pharmaceutical-export-tariffs-sweeping-free-trade-pact-india)

---

### ðŸ‡ºðŸ‡¸ STAT+: Lilly, Repertoire strike $2 billion autoimmune alliance

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 16:03
- **é‡è¦æ€§**: â­â­

> And other biotech news, brought to you by The Readout

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/29/biotech-news-lilly-repertoire-strike-autoimmune-alliance/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about AstraZeneca investing in China, an abandoned overdose antidote, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 14:23
- **é‡è¦æ€§**: â­â­

> AstraZeneca will invest $15 billion in China through 2030 to expand medicines manufacturing and research and development

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/29/astrazeneca-hologen-kickbacks-overdose-lilly-china/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Medicare drug prices, the EU-India trade deal, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 14:00
- **é‡è¦æ€§**: â­â­

> The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/28/medicare-pharma-india-europe-novo-lilly-advertising/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about pharma lobbying, an FDA gene-editing pathway, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 14:05
- **é‡è¦æ€§**: â­â­

> The pharmaceutical industry, long one of the most powerful lobbies in Washington, is spending more than ever to influence the nationâ€™s capital

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/26/pharma-lobbying-novo-genes-fda-patents/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about drug shortages, llama antibodies for developing meds, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 14:27
- **é‡è¦æ€§**: â­â­

> The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in 2024

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/23/moderna-vaccines-cigna-shortages-cancer-obesity-weight/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about a Roche obesity drug, a clash over 340B claims data, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 14:17
- **é‡è¦æ€§**: â­

> Roche plans to launch Phase 3 studies of its leading obesity candidate this quarter after the drug led to significant weight loss in a mid-stage trial

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/27/roche-obesity-menopause-china-lilly-340b-hospitals-bausch/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ Novo gets Chamber of Commerce backing in bid to bring IRA challenge to Supreme Court

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 14:36

> On Wednesday, the U.S. Chamber of Commerce filed an amicus brief calling on the Supreme Court to review a lower court decision that previously rejected Novo Nordisk's challenge of drug pricing provisions in the Inflation Reduction Act. As with other challenges to the IRA, the Chamber argued that the negotiations baked into the law are â€œillusory."

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/novo-gets-chamber-commerce-backing-bid-bring-ira-challenge-supreme-court)

---

### ðŸ‡ºðŸ‡¸ Hims &amp; Hers uses another Super Bowl ad to tackle healthcare affordability

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 13:21

> The minute-long ad, which debuted online Thursday ahead of its broadcast premiere during the Feb. 8 game, starts with a stark claim: â€œRich people live longer,â€ said by the adâ€™s narrator, the rapper and actor Common.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/hims-hers-uses-another-super-bowl-ad-tackle-healthcare-affordability)

---

### ðŸ‡ºðŸ‡¸ Takeda, still in a Vyvanse slog, lifts guidance as it looks to new wave of growth

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 11:26

> The gap between Vyvanse generic sales declines and growth from new products is narrowing, the Japanese company said on its third-quarter 2025 earnings call, which detailed financial performance from the nine months ending on Dec. 31.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/takeda-still-vyvanse-slog-lifts-guidance-it-looks-ahead-new-growth)

---

### ðŸ‡ºðŸ‡¸ As Roche eyes busy 2026, Vabysmo undershoots targets and Tecentriq fails early lung cancer study

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 10:41

> Roche is looking to a busy 2026 after 10 new molecules entered late-stage testing last year and as a potential launch of closely watched breast cancer candidate giredestrant draws near. But behind another strong earnings report, a miss from the star eye drug Vabysmo stood out.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/roche-eyes-busy-2026-vabysmo-undershoots-targets-tecentriq-fails-early-lung-cancer-study)

---

### ðŸ‡ºðŸ‡¸ Bayer broadcasts patient stories with Tony Romo calling plays in Nubeqa drive

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-29 10:12

> Bayer has unveiled the next play in its Nubeqa marketing strategy, tapping NFL quarterback-turned-CBS commentator Tony Romo for a campaign in support of its fast-growing prostate cancer drug.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/bayer-broadcasts-patient-stories-tony-romo-calling-plays-nubeqa-drive)

---

### ðŸ‡ºðŸ‡¸ The new rules of biopharma M&amp;A: 4 trends driving dealmaking this year

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 13:36

> As biopharma M&amp;A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and commercialization process.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/biotech/new-rules-biopharma-ma-4-trends-driving-deal-making-year)

---

### ðŸ‡ºðŸ‡¸ Advocacy group files FOIA lawsuit to gain further clarity on Trump administration's MFN pricing deals

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 15:28

> Consumer advocacy organization Public Citizen has filed a Freedom of Information Act lawsuit against the Department of Health and Human Services and the Department of Commerce&nbsp;for failing to provide documents related to President Donald Trumpâ€™s most-favored nation drug pricing deals with Pfizer and Eli Lilly.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/public-citizen-files-foia-lawsuits-against-trump-administration-mfn-pricing-deals-pfizer)

---

### ðŸ‡ºðŸ‡¸ Halozyme catches M&amp;A wave to snap up Surf Bio in delivery tech deal worth up to $400M

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 12:05

> Shortly after acquiring Elektrofi to beef up its subcutaneous drug delivery offerings, Halozyme Therapeutics has struck another deal to purchase Surf Bio.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/halozyme-catches-ma-wave-snap-surf-bio-delivery-tech-deal-worth-400m)

---

### ðŸ‡ºðŸ‡¸ American Academy of Pediatrics' updated immunization schedule rebukes CDC's drastic cutbacks

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 13:15

> The pediatric medical group recommends children be vaccinated against 18 diseases, as opposed to the federal government's recent reduction to 11.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/providers/american-academy-pediatrics-updated-immunization-schedule-rebukes-cdcs-drastic-changes)

---

### ðŸ‡ºðŸ‡¸ Teva, after 3rd straight year of growth, expects downturn in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 11:01

> With a third consecutive year of sales growth under its belt, the company is expecting flat or slightly down revenues in 2026, it said.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/teva-third-year-growth-innovative-products-expects-downturn-2026)

---

### ðŸ‡ºðŸ‡¸ Ro serves up Super Bowl GLP-1 campaign starring Serena Williams

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 10:58

> Ro is bringing Serena Williams to the Super Bowl. Months after partnering with Williams, Ro has secured airtime at Super Bowl LX to showcase how the 23-time Grand Slam tennis championâ€™s life changed after taking GLP-1 drugs sourced from the telehealth company.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/ro-serves-serena-williams-super-bowl-glp-1-campaign)

---

### ðŸ‡ºðŸ‡¸ Cellares' series D round draws $257M as cell therapy contractor takes operations global

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-28 08:52

> With Cellares preparing to begin commercial-stage production in 2027, the California-based cell therapy contract manufacturer has taken a major step toward that goal, raising $257 million in a series D round.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/cellares-series-d-round-draws-257m-it-readies-commercial-production)

---

### ðŸ‡ºðŸ‡¸ Boehringer Super Bowl ad recruits Octavia Spencer, SofÃ­a Vergara for mission to boost kidney testing

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 14:38

> Boehringer Ingelheimâ€™s mission for Super Bowl LX viewers, should they choose to accept it, is to learn more about urine albumin-to-creatinine ratio screening to monitor kidney health in people with certain risk factors.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/marketing/boehringer-super-bowl-ad-recruits-octavia-spencer-sofia-vergara-mission-boost-kidney)

---

### ðŸ‡ºðŸ‡¸ Trump administration rolls out 15 more high-profile drugs for IRA price negotiations

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 17:14

> Even as the Trump administration works to implement its most-favored-nation pricing system, the U.S. government continues to advance efforts to negotiate Medicare drug prices as enabled by the Inflation Reduction Act.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/trump-administration-rolls-out-15-more-high-profile-drugs-ira-price-negotiations)

---

### ðŸ‡ºðŸ‡¸ China regulators suspend sale of Sun Pharma's dementia med after site inspection

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 11:13

> Chinaâ€™s National Medical Products Administration suspended the import, sale and use of Sun's rivastigmine hydrogen tartrate capsules after a virtual site inspection uncovered manufacturing shortfalls.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/manufacturing/chinese-regulators-suspend-sale-sun-pharmas-dementia-med-after-site-inspection)

---

### ðŸ‡ºðŸ‡¸ Servier delivers 16% revenue jump, firming up â‚¬10B ambition by 2030

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-27 10:09

> After posting 16.2% revenue growth in the last financial year, Servier President Olivier Laureau said the company has moved â€œone important step closerâ€ to achieving an ambitious goal for 2030.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.fiercepharma.com/pharma/servier-delivers-16-revenue-jump-firming-eu10b-ambition-2030)

---

### ðŸ‡ºðŸ‡¸ STAT+: States are the next vaccine battleground

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 17:07

> This is the web edition of STAT's D.C. Diagnosis newsletter.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/29/state-vaccine-mandates-health-care-ice-minnesota-dc-diagnosis-newsletter/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Oz, other officials meet with key senators to push Trumpâ€™s ideas for lower drug prices

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 16:30

> Trump wants lawmakers to force pharma companies to lower their prices, but it's not clear the GOP is on board.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/29/mehmet-oz-senate-finance-committee-meeting-most-favored-nations-drug-pricing/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: How Opvee, Indiviorâ€™s powerful overdose antidote, went bust

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-29 09:30

> Opvee reverses opioid overdose more quickly than Narcan. It also can cause withdrawal symptoms. Harm reduction advocates fought it, and won.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/29/why-opvee-overdose-antidote-failed-harm-reduction-community-opposition/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Eli Lilly expands work on gene therapies for hearing

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 14:49

> And other biotech news brought to you by The Readout

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/28/biotech-news-eli-lillly-expands-gene-therapy-for-hearing/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: More high-income countries have used compulsory licenses to gain access to meds, study finds

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 13:00

> More high-income countries have used compulsory licenses to gain access to meds, study finds.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/28/pharma-compulsory-licenses-patents-medicines-wto/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Startup Altido Therapeutics pursues CAR-T for glioblastoma tumors

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-28 09:30

> Glioblastoma is almost always fatal. Altido Bio is trying to commercialize a CAR-T cell therapy that has shown rare promise.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/28/gene-therapy-nick-leschly-startup-altido-therapeutics-targets-glioblastoma/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: New startup to develop a GLP-1 drug for addiction

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 14:40

> And other biotech news brought to you by The Readout newsletter

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/27/biotech-news-glp-1-drug-for-addiction-startup/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Roche moves obesity drug to pivotal trials after mid-stage success

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-27 08:08

> Roche plans to launch pivotal studies of an experimental weight loss drug after a successful mid-stage trial.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/27/roche-ct388-trials-weight-loss-obesity/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Hospital group wants Trump administration to block a new Lilly policy on 340B claims data

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 21:11

> The American Hospital Association is asking the Trump administration to stop Eli Lilly from enacting a new policy as part of the 340B drug discount program.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/26/pharma-lilly-medicines-hospitals-340b/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Launch of Wegovy pill looks to be going strong so far

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-26 14:30

> And more biotech news brought to you by The Readout

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/26/biotech-news-wegovy-pill-launch-holds-promise-novo-nordisk/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 17:19

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/pharmalot/2026/01/23/pharma-biotech-jobs-teva-novartis-novo-lilly/?utm_campaign=rss)

---

### ðŸ‡ºðŸ‡¸ STAT+: Insurers blame drugmakers, hospitals for high prices

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 15:26

> Plus more biotech news updates, brought to you by The Readout

ðŸ”— [é˜…è¯»åŽŸæ–‡](https://www.statnews.com/2026/01/23/biotech-news-insurers-blame-drugmakers-hospitals-for-prices/?utm_campaign=rss)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-01-30 04:08:00*